Immunic (IMUX)
NASDAQ:IMUX
Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$1.00
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.00
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.51 - $1.51
Previous CloseN/A
Volume261.21K
Average Volume (3M)2.57M
Market Cap
$144.82M
Enterprise Value$79.45M
Total Cash (Recent Filing)$15.48M
Total Debt (Recent Filing)$684.00K
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding130,464,830
10 Day Avg. Volume2,798,560
30 Day Avg. Volume2,567,721
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-124.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.67
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.89K
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$4.38Price Target Upside337.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dual Mechanism And NeuroprotectionAnalyst highlights a differentiated dual mechanism that may both protect nerve cells and reduce inflammation, potentially offering improved disability outcomes compared with current oral therapies.
Pivotal Trial ReadoutsAnalyst believes pivotal late-stage trial readouts from the fully enrolled development program could be a major catalyst if they confirm clinical benefit and tolerability.
Prior Clinical Evidence And MRI OutcomesAnalyst notes mid-stage and prior trials showed reductions in MRI lesion activity and fewer relapses with tolerability similar to placebo, supporting potential competitiveness against established oral options.
Bears Say
Competitive Market PressureAnalyst notes the multiple sclerosis treatment market is crowded with established therapies and generics, which could limit adoption even if clinical signals are positive.
Efficacy Readout UncertaintyAnalyst points out noisy relapse results in early studies and the possibility of lower contemporary relapse rates in trials, increasing the risk that pivotal efficacy readouts may be inconclusive.
Financing And Valuation OverhangAnalyst warns that a financing overhang and reduced price targets after updating share count and launch assumptions create uncertainty that could exert downward pressure on the stock.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.51 and its highest was $1.51 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $144.82M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is May 07, 2026 which is in 16 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Feb 26, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.01.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.08.
How many shares outstanding does Immunic have?
Immunic has 130,464,830 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 4.066%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.38 (337.50% Upside)
$4.38 (337.50% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.04%
12-Months-Change
Fundamentals
Return on Equity
-1197.81%
Trailing 12-Months
Asset Growth
-41.15%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$4.38
▲(337.50% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
0.97% Insiders
3.96% Mutual Funds
<0.01% Other Institutional Investors
91.08% Public Companies and Individual Investors